Key Points: Nearly half of all patients with CKD who progress to kidney failure initiate dialysis in an unplanned fashion, which is associated with poor outcomes. Machine learning models using routinely collected data can accurately predict 6- to 12-month kidney failure risk among the population with advanced CKD. These machine learning models retrospectively deliver advanced warning on a substantial proportion of unplanned dialysis events. Background: Approximately half of all patients with advanced CKD who progress to kidney failure initiate dialysis in an unplanned fashion, which is associated with high morbidity, mortality, and health care costs. A novel prediction model designed to identify patients with advanced CKD who are at high risk for developing kidney failure over short time frames (6–12 months) may help reduce the rates of unplanned dialysis and improve the quality of transitions from CKD to kidney failure. Methods: We performed a retrospective study using machine learning random forest algorithms incorporating routinely collected age and sex data along with time-varying trends in laboratory measurements to derive and validate 6- and 12-month kidney failure risk prediction models in the population with advanced CKD. The models were comprehensively characterized in three independent cohorts in Ontario, Canada—derived in a cohort of 1849 consecutive patients with advanced CKD (mean [SD] age 66 [15] years, eGFR 19 [7] ml/min per 1.73 m2) and validated in two external advanced CKD cohorts (n=1356; age 69 [14] years, eGFR 22 [7] ml/min per 1.73 m2). Results: Across all cohorts, 55% of patients experienced kidney failure, of whom 35% involved unplanned dialysis. The 6- and 12-month models demonstrated excellent discrimination with area under the receiver operating characteristic curve of 0.88 (95% confidence interval [CI], 0.87 to 0.89) and 0.87 (95% CI, 0.86 to 0.87) along with high probabilistic accuracy with the Brier scores of 0.10 (95% CI, 0.09 to 0.10) and 0.14 (95% CI, 0.13 to 0.14), respectively. The models were also well calibrated and delivered timely alerts on a significant number of patients who ultimately initiated dialysis in an unplanned fashion. Similar results were found upon external validation testing. Conclusions: These machine learning models using routinely collected patient data accurately predict near-future kidney failure risk among the population with advanced CKD and retrospectively deliver advanced warning on a substantial proportion of unplanned dialysis events. Optimal implementation strategies still need to be elucidated.
Introduction Tacrolimus is an immunosuppressant commonly administered in transplant recipients. Given its narrow therapeutic range and susceptibility to various influencing variables, determining its optimal dosage is challenging. This systematic review seeks to identify effective analytical modelling techniques and methods for optimal tacrolimus dose prediction in solid transplant recipients. Methods and analysis This review will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria. The study will review the literature published from database inception to 11 March 2024, that assesses predictive models of tacrolimus dosing through analytical modelling techniques. We will include both randomised and non-randomised, as well as cross-sectional, qualitative and before-and-after studies and will perform our searches in four main databases—Ovid/MEDLINE, PubMed/MEDLINE, Scopus, Embase and Web of Science, and search engines including Centers for Disease Control (CDC) and Google Scholar. Papers that are not published in English or French are excluded from this study. A narrative synthesis and meta-analysis will be done if the extracted information permits such analysis. Conference abstracts will be ignored unless they are recent (published within 2 years of the search date). Ethics and dissemination Ethics clearance is not required for this study as no primary data will be collected. The completed manuscript will be published, and the results of the study will be presented at conferences. Study registration International Prospective Register of Systematic Reviews (PROSPERO), CRD42024537212.
Background: Primary aldosteronism(PA) screening is recommended but disease prevalence exceeds the availability of adrenal vein sampling(AVS). Methods: An AVS optimal allocation tool for health systems was developed using administrative data and AVS registries from Calgary and Taiwan. Four easily-definable phenotypes of PA based on an elevated aldosterone-renin-ratio (ARR), and the presence/absence of hypokalemia or adrenal mass were identified, representing progressively severe PA and stepwise increasing rates of AVS-defined lateralization. Using supply-and-demand principles, a customizable, web-based tool was developed that considers PA referral volume, PA phenotype prevalence, maximum AVS available/year, AVS success rate, and desired rate of finding unilateral disease. Results: The most prevalent phenotype of PA was characterized by an elevated ARR and hypokalemia but no adrenal mass (41.9 [39.9–43.9]%); hypokalemia and adrenal mass accounted for (15.6[14.4-16.9]%) of cases. There was a progressive increase in AVS lateralization rate with increasing severity of phenotype observed in both the Calgary and Taiwan data, ranging from (20-39%) in those with PA without hypokalemia or adrenal mass to (70-90%) in those with hypokalemia and adrenal mass. After accounting for institution-specific lateralization rates and allowing for system-level differences in high- and low-volume PA referrals, and high- and low AVS availability, the customizable AVS allocation tool was able to generate individualized strategies ranging from restrictive (exclusive reservation of AVS for cases with hypokalemia and adrenal mass) to more inclusive strategies (assigning a proportion of AVS allocation to less severe PA cases). Conclusions: An AVS allocation tool that uses common, simple, and globally available PA case data may assist in health system AVS program case allocation for maximum equity and wait-list control. GRAPHICAL
Background: Tacrolimus dose optimization remains challenging due to its narrow therapeutic range and multiple influencing variables. This systematic review aimed to identify effective analytical modeling techniques for optimal tacrolimus dose prediction in solid organ transplant recipients. Methods: Two independent researchers conducted a comprehensive review of studies examining analytical models that optimize tacrolimus dosing, searching Medline, Scopus, Embase, Web of Science, and PubMed. Results: In total, 115 studies met the inclusion criteria. Pharmacokinetic models (74 studies), particularly two-compartment with Bayesian forecasting, were most frequently used. Machine learning (ML) approaches, with increasing adoption, have demonstrated promising improved predictive accuracy. Key predictive variables included CYP3A5 genotype, hematocrit levels, post-operative days, and weight; however, the significance of genomic features seemed to diminish progressively as therapeutic drug monitoring calibrates dosing in the months following post-transplant. Only ten studies performed external validation, and none incorporated adherence data or predicted long-term graft outcomes. Conclusions: Clinical deployment of predictive models for tacrolimus dosing remains uncommon. In research, pharmacokinetic models remain prevalent, with ML approaches showing early incremental promise. Limited external validation raises generalizability concerns. Future research should prioritize outcome-based evaluation metrics rather than error metrics.